Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Gastroenterology

• Publication date

  2013-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1053/j.gastro.2013.01.021PMID 23333348PMCID PMC3633736
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Increasing Burden of Mortality From Viral Hepatitis in the United States Between 1999 and 2007

  2012cited by this paper
• Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges.

  2012cited by this paper
• Fibrosis‐dependent mechanisms of hepatocarcinogenesis

  2012cited by this paper
• Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C.

  2011cited by this paper
• Management of hepatocellular carcinoma: An update

  2011cited by this paper
• A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma.

  2011cited by this paper
• Excess mortality in patients with advanced chronic hepatitis C treated with long‐term peginterferon

  2011cited by this paper
• NF-κB in the liver—linking injury, fibrosis and hepatocellular carcinoma

  2011cited by this paper
• The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective.

  2010cited by this paper
• Evolving challenges in hepatic fibrosis

  2010cited by this paper
• Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States

  2010cited by this paper
• Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression.

  2010cited by this paper
• Nearest Template Prediction: A Single-Sample-Based Flexible Class Prediction with Confidence Assessment

  2010cited by this paper
• Screening and diagnosis of hepatocellular carcinoma

  2009cited by this paper
• Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005.

  2009cited by this paper
• Targeting liver fibrosis: Strategies for development and validation of antifibrotic therapies

  2009cited by this paper
• Whole-Genome Gene Expression Profiling of Formalin-Fixed, Paraffin-Embedded Tissue Samples

  2009cited by this paper
• Use of archived specimens in evaluation of prognostic and predictive biomarkers.

  2009cited by this paper
• A seven‐gene signature (cirrhosis risk score) predicts liver fibrosis progression in patients with initially mild chronic hepatitis C

  2009cited by this paper
• Systematic review: non‐invasive methods of fibrosis analysis in chronic hepatitis C

  2009cited by this paper
• Liver cirrhosis.

  2008cited by this paper
• Recurrence of hepatocellular carcinoma.

  2008cited by this paper
• Design and endpoints of clinical trials in hepatocellular carcinoma.

  2008cited by this paper
• The Use of Genomics in Clinical Trial Design

  2008cited by this paper
• Gene expression in fixed tissues and outcome in hepatocellular carcinoma.

  2008cited by this paper
• Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis.

  2008cited by this paper
• Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis.

  2008cited by this paper
• Novel advancements in the management of hepatocellular carcinoma in 2008.

  2008cited by this paper
• Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma

  2008cited by this paper
• The model for end‐stage liver disease (MELD)

  2007cited by this paper
• Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies.

  2006cited by this paper
• GenePattern 2.0

  2006cited by this paper
• Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance.

  2004cited by this paper
• Hepatocellular carcinoma

  2003cited by this paper
• The burden of selected digestive diseases in the United States.

  2002cited by this paper
• Hepatocellular carcinoma in Italian patients with cirrhosis.

  1991cited by this paper
• Transection of the oesophagus for bleeding oesophageal varices

  1973cited by this paper

• Hydroxylsafflower yellow A modulates tumor vascularization in liver cancer through intercellular communication and extracellular matrix-receptor interactions.

  2025cites this paper
• Considerations on the Clinical Translation and Statistical Rigor of the PAaM Score for HCC Risk Stratification.

  2025cites this paper
• Cost-Effectiveness of Risk-Score-Based Surveillance Strategies for Hepatocellular Carcinoma in Patients with Chronic Hepatitis B.

  2025cites this paper
• Reply to Zheng and Shan and to Bao et al.

  2025cites this paper
• ADVANCING CURCUMIN APPLICATIONS IN HEPATOCELLULAR CARCINOMA: INSIGHTS INTO PHARMACOKINETICS, PHARMACODYNAMICS AND NANODELIVERY SYSTEMS

  2025cites this paper
• A Case Report of a Rapid Development of Hepatocellular Carcinoma (HCC) Within Six Months of Hepatitis C Cure in an Individual With Risk Factors

  2025cites this paper
• Immunomodulatory role of vitamin D and emerging immunotherapies in hepatocellular carcinoma

  2025cites this paper
• Prognostic assessment of early-stage liver cirrhosis induced by HCV using an integrated model of CX3CR1-associated immune infiltration genes

  2025cites this paper
• Improving risk stratification and detection of early HCC using ultrasound-based deep learning models

  2025cites this paper
• AI-based phenotyping of hepatic fiber morphology to inform molecular alterations in metabolic dysfunction-associated steatotic liver disease.

  2025cites this paper
• A liver gene signature links liver cancer risk in chronic viral hepatitis to intrahepatic IgA plasma cells

  2025cites this paper
• Emerging role of molecular diagnosis and personalized therapy for hepatocellular carcinoma

  2024cites this paper
• Epidermal Growth Factor Receptor Inhibition With Erlotinib in Liver: Dose De-Escalation Pilot Trial as an Initial Step in a Chemoprevention Strategy

  2024cites this paper
• Cytoplasmic retention of the DNA/RNA-binding protein FUS ameliorates organ fibrosis in mice

  2024cites this paper
• Unlocking the potential of oncology biomarkers: advancements in clinical theranostics

  2024cites this paper
• New insights into potential biomarkers and their roles in biological processes associated with hepatitis C-related liver cirrhosis by hepatic RNA-seq-based transcriptome profiling

  2024cites this paper
• Phase 3 Validation of PAaM for Hepatocellular Carcinoma Risk Stratification in Cirrhosis

  2024cites this paper
• SIMarker: Cellular similarity detection and its application to diagnosis and prognosis of liver cancer

  2024cites this paper
• Atlas of mildly and highly insoluble matrisome driving liver fibrosis

  2024cites this paper
• Role of biomarkers in the diagnosis and management of HCC

  2024cites this paper
• An atlas of the human liver diurnal transcriptome and its perturbation by hepatitis C virus infection

  2024influential citation
• Tumor suppressive role of the antimicrobial lectin REG3A targeting the O-GlcNAc glycosylation pathway

  2024cites this paper
• Identification of SOX9-related prognostic DEGs and a prediction model for hepatitis C-induced early-stage fibrosis.

  2024cites this paper
• DeMoS: dense module based gene signature detection through quasi-clique: an application to cervical cancer prognosis

  2024cites this paper
• Inflammation-related prognostic markers in resected hepatocellular carcinoma

  2023cites this paper
• Wide surgical margins improve prognosis for HCC with microvascular invasion.

  2023cites this paper
• Insights into Hepatocellular Carcinoma in Patients with Thalassemia: From Pathophysiology to Novel Therapies

  2023cites this paper
• Positive selection of somatically mutated clones identifies adaptive pathways in metabolic liver disease

  2023influential citation
• Fibroblast‐specific adipocyte enhancer binding protein 1 is a potential pathological trigger and prognostic marker for liver fibrosis independent of etiology

  2023cites this paper
• Unmet Needs in the Post-Direct-Acting Antiviral Era: Hepatocarcinogenesis After Hepatitis C Virus Eradication.

  2023cites this paper
• PBMCs gene expression signature of advanced cirrhosis with high risk for clinically significant portal hypertension in HIV/HCV coinfected patients: A cross-control study.

  2023cites this paper
• Polo-like kinase-1 mediates hepatitis C virus-induced cell migration, a drug target for liver cancer

  2023influential citation
• Development of Prognostic Features of Hepatocellular Carcinoma Based on Metabolic Gene Classification and Immune and Oxidative Stress Characteristic Analysis

  2023cites this paper
• A Practical Risk Classification of Early Recurrence in Hepatocellular Carcinoma Patients with Microvascular invasion after Hepatectomy: A Decision Tree Analysis

  2022cites this paper
• Risk stratification and early detection biomarkers for precision hepatocellular carcinoma screening.

  2022cites this paper
• Risk of hepatocellular carcinoma after hepatitis C virus cure

  2022cites this paper
• Differentiating between liver diseases by applying multiclass machine learning approaches to transcriptomics of liver tissue or blood-based samples

  2022cites this paper
• Biomarkers in Hepatopancreatobiliary Carcinomas

  2022cites this paper
• A new prognostic model predicting hepatocellular carcinoma early recurrence in patients with microvascular invasion who received postoperative adjuvant transcatheter arterial chemoembolization.

  2022cites this paper
• Hepatocellular Carcinoma: Aetiology and Mechanisms of Development. A Literature Review

  2022cites this paper
• Liver cancer risk-predictive molecular biomarkers specific to clinico-epidemiological contexts.

  2022cites this paper
• Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease

  2022cites this paper
• Prognostic Value of Stem Cell Index-Related Characteristics in Primary Hepatocellular Carcinoma

  2022cites this paper
• Characteristics and Clinical Significance of T-Cell Receptor Repertoire in Hepatocellular Carcinoma

  2022cites this paper
• A new preclinical model of western diet‐induced progression of non‐alcoholic steatohepatitis to hepatocellular carcinoma

  2022cites this paper
• A Multi-Molecular Fusion to Detect Transcriptomic Signature in Tissue-Specific Cancer

  2022cites this paper
• Impact of HCV Infection on Hepatocyte Polarity and Plasticity

  2022cites this paper
• Cell-based cccDNA reporter assay combined with functional genomics identifies YBX1 as HBV cccDNA host factor and antiviral candidate target

  2022cites this paper
• A Unique Immune-Related Gene Signature Represents Advanced Liver Fibrosis and Reveals Potential Therapeutic Targets

  2022cites this paper
• Exploring mechanisms of Chaihu-Shugan-San against liver fibrosis by integrated multi-omics and network pharmacology approach

  2022cites this paper
• Classification and survival prediction in early‐stage cirrhosis by gene expression profiling

  2022cites this paper
• Integrated analysis of single-cell transcriptome of liver cancer and cirrhosis reveals cell lineage similarity and prognostic-associated subpopulations

  2022cites this paper
• Conventional and artificial intelligence-based imaging for biomarker discovery in chronic liver disease

  2022cites this paper
• Atorvastatin favorably modulates a clinical hepatocellular carcinoma risk gene signature

  2022cites this paper
• Biomarkers for the Detection and Management of Hepatocellular Carcinoma in Patients Treated with Direct-Acting Antivirals

  2022cites this paper
• Hepatocellular carcinoma chemoprevention by targeting the angiotensin-converting enzyme and EGFR transactivation

  2022cites this paper
• Fibrogenic signals persist in DAA-treated HCV patients after sustained virological response.

  2021cites this paper
• Identification and Characterization of Robust Hepatocellular Carcinoma Prognostic Subtypes Based on an Integrative Metabolite‐Protein Interaction Network

  2021cites this paper
• Regression of Hepatic Fibrosis and Evolution of Cirrhosis: A Concise Review

  2021cites this paper
• Identification of New Biomarker for Prediction of Hepatocellular Carcinoma Development in Early-Stage Cirrhosis Patients

  2021cites this paper
• Preoperative nomogram for microvascular invasion prediction based on clinical database in hepatocellular carcinoma

  2021cites this paper
• Liver cell circuits and therapeutic discovery for advanced liver disease and cancer

  2021cites this paper
• Molecular signature predictive of long-term liver fibrosis progression to inform anti-fibrotic drug development.

  2021cites this paper
• A blood-based prognostic liver secretome signature predicts long-term risk of hepatic decompensation in cirrhosis.

  2021cites this paper
• A blood-based prognostic liver secretome signature and long-term hepatocellular carcinoma risk in advanced liver fibrosis.

  2021cites this paper
• Molecular characterization of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis.

  2021cites this paper
• Role of Hepatocyte‐Derived Osteopontin in Liver Carcinogenesis

  2021cites this paper
• Data types and resources

  2021cites this paper
• A survey of optimal strategy for signature-based drug repositioning and an application to liver cancer

  2021cites this paper
• Cost-Effectiveness of a Serum Biomarker Test for Risk-Stratified Liver Ultrasound Screening for Hepatocellular Carcinoma.

  2021cites this paper
• A subset of liver resident natural killer cells is expanded in hepatitis C-infected patients with better liver function

  2021cites this paper
• Molecular classification of hepatocellular carcinoma: prognostic importance and clinical applications

  2021cites this paper
• Using Integrated Multi-Omics Data Analysis to Identify 5-gene Signature for Predicting Survival of Patients with Hepatocellular Carcinoma

  2021cites this paper
• Tracking Down the Epigenetic Footprint of HCV-Induced Hepatocarcinogenesis

  2021cites this paper
• Precision Oncology

  2021cites this paper
• Dynamically remodeled hepatic extracellular matrix predicts prognosis of early-stage cirrhosis

  2021cites this paper
• Persistent RNA virus infection is short-lived at the single-cell level but leaves transcriptomic footprints

  2021cites this paper
• Effects of Subnormothermic Regulated Hepatic Reperfusion on Mitochondrial and Transcriptomic Profiles in a Porcine Model

  2021cites this paper
• A human liver cell-based system modeling a clinical prognostic liver signature for therapeutic discovery

  2021cites this paper
• Profibrotic Signaling and HCC Risk during Chronic Viral Hepatitis: Biomarker Development

  2021cites this paper
• Hepatocellular carcinoma risk after viral response in hepatitis C virus-advanced fibrosis: Who to screen and for how long?

  2021cites this paper
• Screening for hepatocellular carcinoma in viral liver disease: any new biomarkers on the horizon?

  2020cites this paper
• Role of epidermal growth factor receptor in liver injury and lipid metabolism: Emerging new roles for an old receptor.

  2020cites this paper
• Sofosbuvir Activates EGFR-Dependent Pathways in Hepatoma Cells with Implications for Liver-Related Pathological Processes

  2020cites this paper
• Hepatitis C Virus and Hepatocellular Carcinoma: When the Host Loses Its Grip

  2020cites this paper
• Biomarkers for Hepatobiliary Cancers

  2020cites this paper
• EGF neutralization antibodies attenuate liver fibrosis by inhibiting myofibroblast proliferation in bile duct ligation mice

  2020cites this paper
• Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma

  2020cites this paper
• Omics‐derived hepatocellular carcinoma risk biomarkers for precision care of chronic liver diseases

  2020cites this paper
• Surveillance for Hepatocellular Carcinoma.

  2020cites this paper
• DeMoS: Dense Module-based Gene Signature Detection through Quasi-Clique: An Application for Cervical Cancer Prognosis

  2020cites this paper
• An Integrated Model Based on a Six-Gene Signature Predicts Overall Survival in Patients With Hepatocellular Carcinoma

  2020cites this paper
• DNA Methylation Profiling of Human Hepatocarcinogenesis

  2020cites this paper
• Four gene intrahepatic metastasis-risk signature predicts hepatocellular carcinoma malignant potential and early recurrence from intrahepatic metastasis.

  2020cites this paper
• Risk Factors, Pathogenesis, and Strategies for Hepatocellular Carcinoma Prevention: Emphasis on Secondary Prevention and Its Translational Challenges

  2020cites this paper
• Surveillance of hepatocellular carcinoma in cirrhotic patients: Current knowledge and future directions

  2020cites this paper
• Immune Checkpoint Inhibition is Safe and Effective for Liver Cancer Prevention in a Mouse Model of Hepatocellular Carcinoma

  2020cites this paper
• Identification and Validation of an Immune-related Prognostic Signature for Hepatocellular Carcinoma

  2020cites this paper
• CC motif chemokine ligand 16 inhibits the progression of liver cirrhosis via inactivating hepatic stellate cells.

  2020cites this paper
• Role of imaging in management of hepatocellular carcinoma: surveillance, diagnosis, and treatment response

  2020cites this paper